Indivior is expected to report Q3 2026 revenue of $326.7 million and earnings per share of $0.93, with the stock trading at $34.56 against a $45.17 average analyst price target.
The primary focus for investors is the sales performance of Sublocade, Indivior’s flagship long-acting injectable, as analysts look for evidence that volume growth can offset pricing headwinds and competitive entry.
Management recently upgraded full-year revenue guidance, setting a high bar for this quarter to prove the "Action Agenda" is successfully accelerating market penetration. Additionally, shareholders are awaiting updates on the closing of the Supernus merger and the subsequent $8.13 special cash dividend.